
## Andreas L Marzinzik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7577843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors. RSC Chemical Biology, 2021, 2, 1661-1668.	4.1	7
2	Fragmentâ€Based Discovery of Nonâ€bisphosphonate Binders of <i>Trypanosoma brucei</i> Farnesyl Pyrophosphate Synthase. ChemBioChem, 2020, 21, 3096-3111.	2.6	8
3	Discovery of Potent and Selective Antibody–Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Medicinal Chemistry Letters, 2019, 10, 1674-1679.	2.8	10
4	Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. Journal of Medicinal Chemistry, 2018, 61, 8120-8135.	6.4	275
5	The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature, 2017, 543, 733-737.	27.8	389
6	Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 454-462.	2.3	59
7	Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nature Chemical Biology, 2010, 6, 660-666.	8.0	110
8	Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay. Journal of the American Chemical Society, 2010, 132, 7043-7048.	13.7	95
9	Library Design for Fragment Based Screening. Current Topics in Medicinal Chemistry, 2005, 5, 751-762.	2.1	195